Market closed

XBiotech/$XBIT

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About XBiotech

XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Ticker

$XBIT

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Austin, United States

Employees

Website

www.xbiotech.com

XBiotech Metrics

BasicAdvanced

$113M

-

-$1.08

1.41 -

Price and volume

Market cap

$113M

Beta

1.41

52-week high

$9.96

52-week low

$3.51

Average daily volume

88K

Financial strength

Current ratio

11.57

Quick ratio

11.505

Total debt to equity

5.205

Interest coverage (TTM)

-70.17%

Management effectiveness

Return on assets (TTM)

-12.03%

Return on equity (TTM)

-15.75%

Valuation

Price to book

0.59

Price to tangible book (TTM)

0.59

Price to free cash flow (TTM)

-3.871

Growth

Earnings per share change (TTM)

41.57%

3-year earnings per share growth (CAGR)

35.78%

XBiotech Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

XBiotech Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

XBiotech News

AllArticlesVideos

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

GlobeNewsWire·8 hours ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Stockholders to Connect

Accesswire·14 hours ago

XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm

Accesswire·14 hours ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XBIT

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for XBiotech stock?

XBiotech (XBIT) has a market cap of $113M as of January 15, 2025.

What is the P/E ratio for XBiotech stock?

The price to earnings (P/E) ratio for XBiotech (XBIT) stock is 0 as of January 15, 2025.

Does XBiotech stock pay dividends?

No, XBiotech (XBIT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next XBiotech dividend payment date?

XBiotech (XBIT) stock does not pay dividends to its shareholders.

What is the beta indicator for XBiotech?

XBiotech (XBIT) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.